Everywhere you look in this administration there are irresponsible people making terrible decisions on life or death matters. And thanks to the major debacles of Pete Hegseth and Kristi Noem and Pam Bondy and Kash Patel keeping everybody occupied, Robert F. Kennedy Jr.., the leading who leads the Department of Health and Human Services has mostly been off the front pages. But make no mistake, his department has done serious long-term damage to American health and safety, and things could get a lot worse. Ju ...

Core Insights - Pfizer faced a significant setback by abandoning its internally developed GLP-1 weight loss drug in April 2025, falling behind competitors like Novo Nordisk and Eli Lilly in a growing market [1][2] - Despite recent challenges, including a 50% decline in stock value since 2021 and upcoming patent expirations, Pfizer quickly pivoted by acquiring a company with a promising GLP-1 candidate, closing the deal in November 2025 [3][4] - Pfizer maintains a market capitalization of $150 billion, indicating its status as a respected industry giant, even amidst fluctuations in the pharmaceutical sector [4][6] Financial Performance - Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced remarkable revenue growth of 99% and 175% respectively in 2025, highlighting strong consumer demand in the GLP-1 market [2] - Pfizer's current stock price is $27.04, with a market cap of $154 billion, a gross margin of 66.23%, and a dividend yield of 6.36% [5][6] - The company has a payout ratio exceeding 100%, which may raise concerns for conservative dividend investors, yet management intends to maintain the dividend [7] Future Outlook - In February 2026, Pfizer announced progress on a long-acting GLP-1 drug, indicating that the company remains on track despite previous setbacks [6] - Long-term investors may find Pfizer appealing due to its industry leadership and potential for consistent dividends over time [7]

Core Viewpoint - Pfizer is positioned as a high-yield investment with a 6.5% dividend yield while also having a promising pipeline for long-term growth despite facing challenges post-COVID era [2][3][4] Financial Performance - Pfizer's shares are currently trading at 9.1 times forward P/E, which is 55% below its peak in 2021 [7] - Revenue expectations are being negatively impacted by patent expirations through 2026, leading to a cautious management outlook [6][7] Product Pipeline - The company has several promising innovations in the pipeline, including oncology treatments and a new Lyme disease vaccine [2][7] - Pfizer aims for $10 billion in oncology revenue by 2030, with several Antibody-Drug Conjugate cancer candidates in Phase 2 and 3 trials [7] Market Sentiment - Despite the underwhelming guidance and challenges, there is potential for recovery gains, making Pfizer an attractive option for investors seeking value and yield [3][4]

Arcturus Therapeutics (NasdaqGM:ARCT) FY Conference March 23, 2026 12:30 PM ET Company ParticipantsJoe Payne - CEOConference Call ParticipantsAdam Walsh - Senior Research AnalystAdam WalshGood morning, and thank you for joining us again for the 38th Annual ROTH Conference. My name is Adam Walsh. I'm a Senior Research Analyst with ROTH, covering the biotechnology sector. Our next presenter is Joe Payne, CEO of Arcturus Therapeutics. Joe, thanks for joining us.Joe PayneAdam, it's good to be with you. Thanks f ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Market Reactions - US stock futures rose approximately 0.4% for the S&P 500 and Nasdaq 100, and 0.2% for the Dow Jones Industrial Average, following a report of Iran's indirect approach to the US regarding conflict resolution [1][2] - The conflict has caused significant volatility in US stocks, with a notable crash in Korea's main benchmark due to geopolitical tensions [2][3] Oil Market Impact - Oil prices increased over 2%, with Brent crude futures near $84 per barrel and West Texas Intermediate futures above $76, as the US announced plans to provide insurance and escorts for oil tankers in the Strait of Hormuz [4][6] - Goldman Sachs does not predict oil prices will exceed $100 per barrel despite the ongoing conflict [12] Labor Market and Earnings - Investors are anticipating an ADP update on private payrolls to gauge labor market health ahead of a crucial jobs report [5] - Earnings reports from companies like Broadcom, Costco, and Alibaba are expected to be muted this week [5] AI and Technology Sector - Foreign investors have sold approximately $3.1 billion in South Korean shares and $3.6 billion in Taiwanese shares, indicating a retreat from high-flying AI markets due to inflation fears [14][15] - Major chipmakers like Samsung Electronics and SK Hynix have seen stock declines of nearly 20% this week, with Taiwan Semiconductor Manufacturing Co. down nearly 7% [16][17]

Market Overview - US stock futures declined slightly, with S&P 500 and Nasdaq 100 down 0.1% and Dow Jones Industrial Average down 0.2% following a volatile trading day on Wall Street [1] - The ongoing conflict involving Iran has contributed to market volatility, with significant impacts observed in global markets, particularly in Korea where the main benchmark experienced its largest one-day drop on record [2] Geopolitical Impact - The conflict has intensified with Israel conducting fresh strikes on Tehran, coinciding with the funeral of Supreme Leader Ali Khameni [2] - Despite reports of Iran's indirect approach to the US for negotiations, US officials remain skeptical, viewing the overture as insufficient given the timing of the ongoing hostilities [3] Oil Market Dynamics - Oil prices have shown fluctuations, with Brent crude futures trading near $82 per barrel and West Texas Intermediate futures around $75, influenced by geopolitical tensions and US promises of protection for oil tankers in the Strait of Hormuz [5][7] - Following President Trump's announcement regarding tanker protection, oil prices saw a reduction in gains, with Brent crude futures easing from $84 to below $82 [7] Economic Indicators - Investors are anticipating an ADP update on private payrolls, which will provide insights into the labor market and influence expectations for Federal Reserve interest rate actions [6] - Earnings reports from companies such as Broadcom, Costco, and Alibaba are expected to be less impactful this week due to the prevailing geopolitical concerns [6] Company-Specific Movements - Strategy (MSTR) stock rose 8% in premarket trading, attributed to a 6% increase in bitcoin [12] - Ross Stores (ROST) saw a 5% increase following better-than-expected fourth-quarter results [12] - Moderna (MRNA) stock increased by 3% after resolving a dispute related to its COVID vaccine, while GitLab (GTLB) shares fell 9% due to anticipated sales slowdown [12]

Market Overview - US stock futures stabilized after a volatile trading day, with S&P 500 and Nasdaq 100 hovering just below flatline, while Dow Jones futures slipped 0.2% following a nearly 1% decline in major US benchmarks on Tuesday [1] - The ongoing conflict in Iran has heightened market volatility, with fresh strikes by Israel and concerns about inflation impacting investor sentiment [2] Oil Market Insights - Oil prices have surged over 2%, with Brent crude futures near $84 per barrel and West Texas Intermediate futures exceeding $76, driven by supply concerns [4] - Goldman Sachs has raised its 2026Q2 average oil price forecast for Brent by $10 to $76 per barrel and for WTI by $9 to $71 per barrel, citing low exports from the Strait of Hormuz and geopolitical uncertainty as key factors [5] Corporate Earnings and Stock Movements - Investors are awaiting the ADP private payrolls report for insights into labor market health, while earnings reports from Broadcom, Costco, and Alibaba are expected to draw attention [5] - Strategy stock rose 8% in premarket trading, benefiting from a 6% rise in bitcoin, while Ross Stores' stock jumped 5% after beating analyst estimates in its fourth-quarter results [6] - Moderna's stock increased by 3% following a resolution of a dispute related to its COVID vaccine, whereas GitLab shares fell 9% due to expectations of slowing sales [7][8] Investment Trends - Foreign investors are retreating from Asia's markets, selling approximately $3.1 billion of South Korean shares and $3.6 billion in Taiwan, amid fears of an oil-driven inflation shock [9] - The selloff has particularly affected high-flying chipmakers, with Samsung Electronics and SK Hynix each experiencing nearly 20% declines, while Taiwan Semiconductor shares are down nearly 7% [10] - Portfolio managers note that aggressive selling of crowded long positions in AI stocks is occurring as concerns about the Iran situation grow, raising questions about the profitability of capital spending in the sector [11]

Market Overview - US stock futures increased slightly, with S&P 500 rising 0.3%, Nasdaq 100 gaining 0.5%, and Dow Jones Industrial Average up 0.2% following stronger-than-expected private payrolls data and reports of Iran's indirect approach to the US for conflict resolution [1][3] Employment Data - ADP reported that the private sector added 63,000 jobs in February, surpassing economist estimates of 50,000, marking the best monthly gain since July 2025 [6][8] - "Service-providing" sectors contributed 47,000 new jobs, while "goods-producing sectors" added 16,000 jobs [7] - Despite the positive job growth, ADP's chief economist noted that hiring is concentrated in a few sectors, and the pay premium for switching jobs reached a record low in February [8] Oil Market Dynamics - Oil prices stabilized after President Trump's announcement to provide insurance and escorts for oil tankers in the Strait of Hormuz, with Brent crude futures trading near $82 per barrel and West Texas Intermediate futures around $75 [5][10] - Following the announcement, Brent crude futures eased to below $82 after reaching $84, while West Texas Intermediate futures fell to $74 from $77 [11] Geopolitical Impact - The ongoing conflict involving Iran has led to significant volatility in US stocks, with some analysts cautioning against relying on political interventions to stabilize the market [4][13] - The geopolitical tensions have also affected Asian markets, with Korea's main benchmark experiencing its largest one-day decline on record due to concerns over the conflict [2][19]

Core Insights - Deep-pocketed investors are showing a bullish sentiment towards Moderna, indicating potential significant developments ahead [1] - The options activity for Moderna is unusually high, with 60% of investors leaning bullish and 30% bearish [2] Options Activity Summary - A total of 10 extraordinary options activities were recorded for Moderna, with 4 puts totaling $442,603 and 6 calls amounting to $345,665 [2] - The average open interest for Moderna options is 1508.67, with a total volume of 3,911.00, indicating strong trading interest [4] Price Movement Expectations - Investors have been targeting a price range for Moderna between $22.0 and $39.0 over the last three months [3] - Significant options trades include a bearish put option with a strike price of $27.00 and a total trade price of $347.9K, alongside various call options with differing sentiments [8] Company Overview - Moderna is a commercial-stage biotech founded in 2010, known for its mRNA technology validated by its COVID-19 vaccine [9] - The company has 35 mRNA development candidates in clinical studies across various therapeutic areas as of August 2025 [9] Analyst Ratings - Analysts have set an average price target of $32.8 for Moderna, with varying ratings from different firms, including a target of $25 from RBC Capital and $63 from Piper Sandler [11][12]